RE: Potential23 Dec 2023 11:12
Firstly, to address any lingering doubt with regards to future funding requirements, on the current trajectory the evidence strongly suggests further funding would no longer be required to support future organic growth before reaching profitability. With a caveat, should the demand for Speedboat Ultraslim exceed current production capacity to such an extent to trigger a requirement for further investment in manufacturing capacity, or for growth by acquisition.
In either scenario, this would be backed up by a material increase in revenues from the current baseline.
This is now without doubt, a very exciting time for the company and its investors.
A few years ago, Baillie Gifford cited Creo as one of the most exciting and innovative companies they had come across in many years and they became a significant shareholder.
But due recently to the worst market conditions for AIM and small cap growth companies in the living memory of most, and due to being a forced seller because of fund redemptions, their stake in the company has been reduced to 1.995%, down from a previous holding of 7.30% in June last year.
In hindsight, I think BG were a little ahead of their time with Creo.
To quote a famous song from Bob Dylan: "The Times They Are A-Changin’"
As has been seen, Creo have got off to a very positive start ahead of the new year with first use cases of Speedboat Ultraslim in the USA and Europe and most recently, Latin America.
These cases provide a great platform for endorsement and I imagine that their phone lines are ringing hot and the management and salesforce teams are working a lot of overtime.
We anticipate a lot of news on progress in the new year and the update from NICE. Although we don't yet know what the outcome of that will be and Speedboat is already being used to great effect in some UK hospitals, we should be reminded of the recent statement from Creo's CEO in this regard:
"Using our technology, initial
health economic data has
demonstrated that the NHS
can save approximately
£5,000 per procedure"
Excerpt from a research note published by Edison on 14th December 2023 that concludes with:
"In November 2023, Speedboat UltraSlim received 510(k) clearance from the FDA for its Speedboat UltraSlim device, close on the heels of the accelerated clearance pathway in Europe (18 months earlier than anticipated). Management has indicated that the validation work and transfer to manufacturing has now been completed and launch activities should pick up pace in the coming weeks, with a full launch anticipated in early 2024 in Europe. We believe this will be swiftly followed by a launch in the US as well as in other geographies such as Asia-Pacific. We see the launch of the UltraSlim version as a key commercial win for Creo, supporting greater top-line traction for the core portfolio in FY24."
https://www.edisongroup.com/research/ultraslim-launch-kicking-off-fy24-momentum/33060/